Boundless Bio Statistics
Total Valuation
Boundless Bio has a market cap or net worth of $54.78 million. The enterprise value is -$8.12 million.
Important Dates
The last earnings date was Tuesday, November 10, 2026, before market open.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Boundless Bio has 23.61 million shares outstanding. The number of shares has increased by 0.85% in one year.
| Current Share Class | 23.61M |
| Shares Outstanding | 23.61M |
| Shares Change (YoY) | +0.85% |
| Shares Change (QoQ) | +3.88% |
| Owned by Insiders (%) | 2.90% |
| Owned by Institutions (%) | 49.90% |
| Float | 16.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.87 |
| P/TBV Ratio | 0.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 33.97, with zero debt.
| Current Ratio | 33.97 |
| Quick Ratio | 33.60 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -64.57% and return on invested capital (ROIC) is -32.71%.
| Return on Equity (ROE) | -64.57% |
| Return on Assets (ROA) | -31.78% |
| Return on Invested Capital (ROIC) | -32.71% |
| Return on Capital Employed (ROCE) | -93.98% |
| Weighted Average Cost of Capital (WACC) | 6.76% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.98M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +101.74% in the last 52 weeks. The beta is 0.46, so Boundless Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | +101.74% |
| 50-Day Moving Average | 2.52 |
| 200-Day Moving Average | 2.01 |
| Relative Strength Index (RSI) | 35.07 |
| Average Volume (20 Days) | 98,874 |
Short Selling Information
The latest short interest is 790,294, so 3.35% of the outstanding shares have been sold short.
| Short Interest | 790,294 |
| Short Previous Month | 788,477 |
| Short % of Shares Out | 3.35% |
| Short % of Float | 4.73% |
| Short Ratio (days to cover) | 4.74 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -58.01M |
| Pretax Income | -55.50M |
| Net Income | -55.50M |
| EBITDA | -56.06M |
| EBIT | -58.01M |
| Earnings Per Share (EPS) | -$2.46 |
Full Income Statement Balance Sheet
The company has $62.89 million in cash and no debt, with a net cash position of $62.89 million or $2.66 per share.
| Cash & Cash Equivalents | 62.89M |
| Total Debt | n/a |
| Net Cash | 62.89M |
| Net Cash Per Share | $2.66 |
| Equity (Book Value) | 61.72M |
| Book Value Per Share | 2.67 |
| Working Capital | 61.72M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$56.93 million and capital expenditures -$470,000, giving a free cash flow of -$57.40 million.
| Operating Cash Flow | -56.93M |
| Capital Expenditures | -470,000 |
| Depreciation & Amortization | 1.95M |
| Net Borrowing | n/a |
| Free Cash Flow | -57.40M |
| FCF Per Share | -$2.43 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Boundless Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.85% |
| Shareholder Yield | -0.85% |
| Earnings Yield | -106.17% |
| FCF Yield | -104.80% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |